EUCTR2006-001514-33-FI进行中（未招募）不适用
A phase III, randomized, parallel group study to compare the therapeutic efficacyof SMB BUDESONIDE-SALMETEROL DPI capsule 300/25µg BID delivered bythe AXAHALER® versus SERETIDE® DISKUS® 500/50µg (Fluticasonepropionate 500µg/Salmeterol 50µg) BID over 12 weeks and to evaluate the safety ofSMB BUDESONIDE-SALMETEROL 300/25µg over an additional period of 12weeks in moderate to severe persistent asthmatic patients. - BUSA
aboratories SMB S.A.0 个研究点目标入组 500 人开始时间: 2006年4月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Male or female, 18-70 years of age inclusive;
- •2) History of moderate to severe persistent asthma for at least 3 months prior to the
- •screening visit;
- •3) Reversibility of at least 12% in FEV1 , following inhalation of 400 µg salbutamol at
- •screening and baseline;
- •4) FEV1 (in each of three consecutive measures) 50%-80% of predicted at screening and baseline (prior to dosing with study medication);
- •5) Able to comply with all study procedures;
- •6) Willing to withhold the use of short acting beta-agonists for at least 6 hours prior to each clinic visit;
- •7) Provide written, informed consent to participate in the study, indicated by a personal signature and date on the patient consent form;
- •8) If the patient is female and of childbearing potential, she must be using an efficient means of birth control and provide a negative pregnancy test at the screening visit and randomisation visit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1) Severe life-threatening asthma or hospitalisation for an asthma exacerbation within 3 months prior to the screening visit and hospitalisation for a related disorder in the past 3 months before screening visit;
- •2) Evidence of any unstable or untreated clinically significant immunological, neoplastic, endocrine, haematological, hepatic, renal, gastrointestinal, neurological or psychiatric abnormalities or medical disease;
- •3) Presence or history of any significant cardiac arrhythmia or diagnosed cardiac disease including coronary artery disease, congestive heart failure and uncontrolled hypertension (defined as having a diastolic blood pressure of 95 mmHg or above or a systolic blood pressure of 140 mmHg or above);
- •4) Respiratory tract infection requiring treatment with antibiotics within 8 weeks prior to the screening visit;
- •5) Any significant respiratory disorder other than asthma;
- •6) Smokers of more than 10 cigarettes/day (or equivalent) or a smoking history of more than 10 pack years;
- •7) Pure seasonal asthma and/or a history of seasonal exacerbation of asthma;
- •8) Use of any of the prohibited medication as detailed in the concomitant medication
- •9) Participation in any other clinical trial within 3 months of the screening visit;
- •10) Participation in any other clinical trial with SMB BUDESONIDE-SALMETEROL DPI;
- •11) Presence of any other condition or illness, which, in the opinion of the investigator would interfere with optimal participation in the study;
- •12) Patients with any sensitivity or allergy to any of the products used within this clinical trial;
- •13) Patients with diabetes mellitus;
- •14) History of drug and/or alcohol abuse.
- •15) Incompliance to PEF tests and study medication (more than 20% of PEF tests or study medication intake missing) during the run-in period;
- •16) Patients who received oral or parenteral steroids in the preceding 8 weeks.
研究者
相似试验
进行中（未招募）
不适用
A phase III, randomized, parallel group study to compare the therapeutic efficacy of SMB BUDESONIDE-SALMETEROL DPI capsule 300/25µg BID delivered by the AXAHALER® versus SERETIDE® DISKUS® 500/50µg (Fluticasone propionate 500µg/Salmeterol 50µg) BID over 12 weeks and to evaluate the safety of SMB BUDESONIDE-SALMETEROL 300/25µg over an additional period of 12 weeks in moderate to severe persistent asthmatic patients. - BUSADiagnosis of moderate to severe persistent asthmaMedDRA version: 8.0Level: PTClassification code 10003553EUCTR2006-001514-33-EEaboratoires SMB S.A500
尚未招募
3 期
Parenteral Nutrition Supplement BFLUID in Post-Operative Participants (Gastrectomy & Colectomy)CTRI/2021/01/030728Otsuka Pharmaceutical India Pvt Ltd
进行中（未招募）
1 期
Evaluating efficacy, pharmacokinetics and safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid ArthritisEUCTR2016-002125-11-CZCelltrion, Inc258
进行中（未招募）
1 期
Evaluating efficacy, pharmacokinetics and safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid ArthritisActive Rheumatoid ArthritisMedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2016-002125-11-EECelltrion, Inc258
进行中（未招募）
1 期
Evaluating efficacy, pharmacokinetics and safety between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients with Active Rheumatoid ArthritisEUCTR2016-002125-11-HUCelltrion, Inc258